logo
logo
A stock ticker logo

Agilent Technologies, Inc.

NYSE•A
CEO: Mr. Rodney Gonsalves
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
連絡先情報
5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, United States
800-227-9770
www.agilent.com
時価総額
$31.57B
PER (TTM)
24.5
30.8
配当利回り
0.9%
52週高値
$160.27
52週安値
$96.43
52週レンジ
24%
順位19Top 5.6%
6.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$1.80B+0.00%
直近4四半期の推移

EPS

$1.08+0.00%
直近4四半期の推移

フリーCF

$175.00M+0.00%
直近4四半期の推移

2026 Q1 決算ハイライト

主なハイライト

Total Revenue Increased 7% Total net revenue reached $1,798M for the quarter, a 7% increase, driven by growth across all segments.
Agilent CrossLab Revenue Strong Agilent CrossLab segment revenue grew 9% to $758M, benefiting from strong growth in services and consumables.
Net Income Slightly Decreased Net income was $305M, a slight decrease from $318M last year, resulting in Basic EPS of $1.08.
Significant Stock Repurchase Activity Repurchased 1.050M shares for $152M under the 2024 program; $1,797M authorization remains available.

リスク要因

Operating Margin Pressure Operating margin fell 3 percentage points to 19.7% due to higher tariffs, wage increases, and restructuring costs.
Cash Flow From Operations Cash provided by operating activities decreased to $268M from $431M last year, impacted by variable pay accruals.
Tariff Impact on Costs Tariff changes adversely impacted Q1 2026 costs of revenue, though full offset is expected during fiscal year 2026.
Increased SG&A Expenses Selling, general, and administrative expenses rose 16% due to corporate infrastructure and transformation initiative costs.

見通し

Tariff Mitigation Strategies Expect to fully offset current tariff impact in FY2026 via supply chain optimization and targeted pricing actions.
FY25 Restructuring Completion Expect to substantially complete FY25 Plan restructuring activities by the end of fiscal year 2026.
Capital Expenditure Forecast Total capital expenditures for the current year are expected to be approximately $500M, focused on manufacturing expansion.
Continued R&D Investment Optimistic about long-term growth, continuing investment in R&D and expanding position in emerging markets globally.

同業比較

売上高 (TTM)

CAH stock ticker logoCAH
$244.49B
+10.1%
TAK stock ticker logoTAK
$30.01B
-2.0%
HLN stock ticker logoHLN
$25.31B
+13.7%

粗利益率 (最新四半期)

INSM stock ticker logoINSM
82.5%
-18.6pp
EW stock ticker logoEW
78.3%
-2.7pp
HLN stock ticker logoHLN
65.0%
+0.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
BDX$57.83B25.96.9%35.6%
TAK$56.14B79.31.6%31.5%
CAH$51.56B31.0-58.9%15.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.5%
緩やかな成長
4四半期純利益CAGR
12.4%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年5月26日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし